# Rivermark Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rivermark-medical

- Industry: Medical Devices & Equipment
- Headquarters: Milwaukee, US
- Website: www.rivermarkmedical.com
- Total disclosed funding: $54M
- Latest round: Series D (May 13, 2026)
- Investors on record: 8

## About

Established in 2021 and based in Wisconsin, US, Rivermark Medical, Inc. is a healthcare company that provides minimally invasive device therapy for treating benign prostatic hyperplasia. The company was founded by its CEO, Adam Kadlec, and Andy Doraiswamy. In May 2026, Rivermark Medical, Inc. raised USD 20 million in series D funding led by new investor Andera Partners, with participation from returning investors Cadence Healthcare Ventures, View Ventures, Anduril Ventures GmbH, American Century Investments, Venture Investors, and Time BioVentures. Other unspecified investors also participated in the round.

Rivermark Medical develops medical devices for the treatment of benign prostatic hyperplasia (BPH), which is a condition often affecting older men that causes an enlarged prostate gland, leading to urinary issues. The company’s product line includes the FloStent System, which is a device designed to treat BPH by restoring normal urinary function. The FloStent System is inserted into the urethra during a minimally invasive procedure.

The company will use the May 2026 funding to advance clinical development of its FloStent device by supporting its ongoing pivotal trial and regulatory approval process in the United States. It also provides capital to prepare for initial commercialization, including manufacturing readiness and market entry. The participation of both new and existing investors ensures continued backing for scaling operations and progressing toward commercial launch.

## Funding rounds

- Series D, May 13, 2026, $20M — Clarevia Ventures, Andera Partners, Time BioVentures, View Ventures, Anduril Ventures GmbH, American Century Investments, Cadence Healthcare Ventures
- Series C, Sep 27, 2024, $30M — Venture Investors, Time BioVentures, View Ventures, Cadence Healthcare Ventures, Anduril Ventures GmbH, American Century Investments
- Series B, Jul 20, 2023, $2.1M — View Ventures, Cadence Healthcare Ventures, Anduril Ventures GmbH
- Series A, Nov 5, 2021, $1.8M — View Ventures, Cadence Healthcare Ventures

## Investors

- View Ventures (https://capitalatlas.ai/funds/view-ventures) — Series A, Series B, Series C, Series D
- Cadence Healthcare Ventures — Series A, Series B, Series C, Series D
- Anduril Ventures GmbH — Series B, Series C, Series D
- Venture Investors — Series C
- Time BioVentures (https://capitalatlas.ai/funds/time-bioventures) — Series C, Series D
- American Century Investments (https://capitalatlas.ai/funds/american-century-investments) — Series C, Series D
- Clarevia Ventures (https://capitalatlas.ai/funds/clarevia-ventures) — Series D
- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series D